DNTH - Conference and earnings call announcements

NEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in three investor conferences. Wells Fargo 21st Annual Healthcare Conference: Marino Garcia, CEO, and Ryan Savitz, EVP, CFO & CBO of Dianthus Therapeutics, will host one-on-one investor meetings on September 8, 2026.Citi's 2026 Biopharma Back to School Conference: Marino Garcia will participate in a fireside chat on Wednesday, September 9, 2026, at 4:20 p.m. ET and host one-on-one investor meetin

NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in two investor conferences in June 2026. Ryan Savitz, EVP, CFO and CBO of Dianthus Therapeutics, will participate in a fireside chat on Wednesday, June 3, 2026, at 12:45 p.m. ET and will host one-on-one investor meetings at the 2026 Jefferies Global Healthcare Conference. Marino Garcia, CEO of Dianthus Therapeutics, will participate in a fireside chat on Tuesday, June 9, 2026, at 2:40 p.m. ET and

NEW YORK and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in the TD Cowen 46th Annual Health Care Conference in Boston. Marino Garcia, CEO of Dianthus Therapeutics, will participate in an analyst-led fireside chat on Tuesday, March 3, 2026 at 1:50 pm EST and will host one-on-one meetings with investors. A webcast of this presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website. About Dianthus The

NEW YORK and WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York City. Marino Garcia, CEO of Dianthus Therapeutics, will participate in an analyst-led fireside chat on Thursday, February 12, 2026 at 10:00 am EST and will host one-on-one meetings with investors. A webcast of this presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website.

NEW YORK and WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in the 44th Annual J.P. Morgan Healthcare conference in San Francisco. Marino Garcia, CEO of Dianthus Therapeutics, will present a corporate overview on Monday, January 12, 2026 at 3:00 pm PST / 6:00 p.m. EST and will host one-on-one meetings with investors. A webcast of this presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website. About

NEW YORK and WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida. Marino Garcia, CEO of Dianthus Therapeutics, will participate in a fireside chat on Tuesday, December 2, 2025 at 2:35 p.m. ET and will host one-on-one meetings with investors. A webcast of this presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website. About Dianthus

NEW YORK and WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the company's participation in four upcoming investor conferences. Marino Garcia, CEO of Dianthus Therapeutics, will participate in fireside chats and host one-on-one investor meetings at the following conferences: Guggenheim 2nd Annual Healthcare Innovation Conference (Boston) - Fireside chat on Tuesday, November 11, 2025 at 3:30 p.m. ETTD Cowen Immunology & Inflammation Summit (Virtual) – Fireside chat on Wednesday, Novem

NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at two upcoming investor events. Baird Biotech Discovery Series - Marino Garcia, Chief Executive Officer, will participate in a fireside chat webcast on Tuesday, May 6 at 1:30 p.m. EDT.Bank of America 2025 Health Care Conference – Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, May 14 at 5:35 p.m. EDT / 2:35 p.m. PDT and will host one-on-one meeting

NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the following investor conferences: TD Cowen 45th Annual Health Care Conference – Marino Garcia, Chief Executive Officer, will participate in a fireside chat on Wednesday, March 5 at 11:50 a.m. ET and host one-on-one meetings with investors in Boston. A webcast of this presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website.Jeff

NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during November and December 2024: Guggenheim Healthcare Innovation Conference on November 11 at 1:30 p.m. ET in Boston, MAJefferies Global Healthcare Conference on November 19 at 9:00 a.m. GMT in London7th Annual Evercore HealthCONx Conference on December 4 at 1

NEW YORK and WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of September: Baird 2024 Global Healthcare Conference on September 11 at 2:00 p.m. ET in New York CityCantor 2024 Global Healthcare Conference on September 17 at 10:55 a.m. ET in New York CityStifel 2024 Virtual Immunology and Inflammation Sum

NEW YORK and WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Thursday, June 6, 2024 at 1:30 p.m. ET in New York. A live webcast of this presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website. About Dianthus TherapeuticsDianthus Therapeutics is a clinical-stage biotechnology comp

NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in the Bank of America Securities 2024 Health Care Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Tuesday, May 14, 2024 at 4:20 p.m. PT in Las Vegas. A live webcast of this presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website. About Dianthus TherapeuticsDianthus Therapeutics is a clinical-stage bi

NEW YORK and WALTHAM, Mass., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in the TD Cowen 44th Annual Health Care Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Monday, March 4, 2024, at 2:50 p.m. EST in Boston. A live webcast of this presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website. About Dianthus TherapeuticsDianthus Therapeutics is a clinical-stage biotechnology